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Summary 47 
Phaeochromocytomas and paragangliomas (PPGLs) are catecholamine secreting 48 
neuroendocrine tumours that predispose to haemodynamic instability. Currently, surgery is 49 
the only available curative treatment, but carries potential risks including hypertensive and 50 
hypotensive crises, cardiac arrhythmias, myocardial infarction and stroke, due to tumoral 51 
release of catecholamines during anaesthetic induction and tumour manipulation. The 52 
mortality associated with surgical resection of PPGL has significantly improved from 20–53 
45% in the early 20th century1 to 0–2.9% in the early 21st century2, largely due to availability 54 
of effective pharmacological agents and advances in surgical and anaesthetic practice. 55 
However, surgical resection of PPGL still poses significant clinical management challenges. 56 
Preoperatively, alpha-adrenoceptor blockade is the mainstay of management, although 57 
various pharmacological strategies have been proposed, based largely on reports derived from 58 
retrospective data sets. To date, no consensus has been reached regarding the ‘ideal’ 59 
preoperative strategy due, in part, to a paucity of data from high quality evidence-based 60 
studies comparing different treatment regimens. Here, based on the available literature, we 61 
address the Clinical Question: Is there an optimal preoperative management strategy for 62 
PPGL? 63 
 64 
What are the goals of preoperative pharmacological therapy? 65 
At a headline level, normalisation of blood pressure and heart rate, and restoration of 66 
intravascular fluid status are the main objectives of preoperative pharmacological 67 
management. Current guidelines suggest adrenergic blockade should be initiated 7-14 days 68 
prior to surgery3. However, the average duration of treatment varies depending on the 69 
regimen adopted, and whether inpatient or outpatient therapy is initiated. Most centres report 70 
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an average preoperative treatment duration of 2-6 weeks.4,6,11 Although in some institutions 71 
treatment may be started even earlier, there is no evidence to suggest that additional benefit is 72 
derived from longer preoperative blockade.4 Similarly, there is no consensus regarding 73 
haemodynamic thresholds that signal adequate blockade, with current published 74 
recommendations based largely on non-controlled studies and institutional experience. 75 
Roizen and colleagues proposed several indicators of adequate preoperative alpha blockade 76 
which included: (1) No in-hospital blood pressure >160/90mmHg for 24 hours prior to 77 
surgery; (2) No orthostatic hypotension with blood pressure <80/45mmHg; (3) No ST 78 
segment or T wave ECG changes for 1-week prior to surgery; (4) No more than 5 premature 79 
ventricular contractions per minute.5 Subsequently, others have suggested a lower 80 
preoperative blood pressure (<130/80mmHg while seated; systolic BP >90mmHg on 81 
standing) and controlled heart rate (60-70 beats per minute while sitting)6, which align with 82 
current Endocrine Society recommendations.3 However, whether preoperative normalisation 83 
of systolic blood pressure is mandatory in all patients has been questioned. Lentschener and 84 
colleagues have proposed that only patients with hypertension-induced organ dysfunction 85 
require systolic blood pressure normalisation prior to surgery, based on their findings that 86 
high preoperative systolic BP per se is not predictive of perioperative haemodynamic 87 
instability.7 88 
 89 
Do all patients with PPGL require preoperative hypotensive drugs? 90 
Current consensus recommends that all hypertensive patients with biochemically confirmed 91 
PPGL should receive preoperative pharmacological management.3 Similarly, in patients with 92 
functional PPGL who are apparently normotensive and asymptomatic, tumour manipulation 93 
may provoke an increase in blood pressure and preoperative medical management is therefore 94 
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recommended.3, 8 Preoperative medical treatment may not be required for patients with non-95 
functioning (defined by negative metanephrine screening), parasympathetic-derived head and 96 
neck paragangliomas or those with exclusive dopamine-secreting tumours.9 However intra-97 
operative anaesthetic vigilance and expertise is still required. 98 
Preoperative blockade with alpha-adrenoceptor antagonists is also standard of care for 99 
management of PPGL in pregnancy. Phenoxybenzamine (PBZ) is the preferred agent and is 100 
safe for the fetus; however, blood pressure control must be carefully monitored to ensure 101 
adequate placental perfusion.6 The optimal timing for surgical resection of a PPGL during 102 
pregnancy is generally considered to be in the second trimester, thereby allowing the 103 
pregnancy to progress to normal term/delivery thereafter. However, if this is not possible, 104 
then treatment with PBZ should continue until the fetus has reached a satisfactory weight; 2 105 
careful discussion between the patient, endocrinologist, obstetrician and anaesthetist 106 
regarding the timing of tumour resection and delivery of the baby by Caesarean section will 107 
be required.2 108 
 109 
Which preoperative hypotensive drugs have been used? 110 
1. Alpha-adrenoceptor antagonists 111 
Phenoxybenzamine (PBZ), a non-competitive α1- and α2-adrenoceptor antagonist, is the 112 
most widely used agent for preoperative blockade. Owing to formation of a permanent 113 
covalent bond with α-adrenoceptors, PBZ has a long duration of action (t1/2 = 24 hours, which 114 
tapers following synthesis of new receptors), and may contribute to sustained hypotension 115 
following tumour removal. Side effects include nasal congestion, CNS sedation, orthostatic 116 
hypotension, reflex tachycardia and, at higher doses, paradoxical hypertension. The starting 117 
dose is 10mg twice daily with a recommended maximum daily dose of 1mg/kg, and average 118 
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dose requirement of 40-60mg/day.10   For the majority of patients pre-treatment with PBZ can 119 
be undertaken on an outpatient basis.11 It is important to note, however, that intraoperative 120 
hypertensive surges (systolic blood pressure >160mmHg) may still occur in patients deemed 121 
to be adequately pre-treated with PBZ9 (Figures 1A and 1B). In addition, high cost and 122 
restricted availability preclude routine use of PBZ in some centres and countries.12 123 
Compared with PBZ, selective α1-adrenoceptor antagonists such as prazosin, terazosin or 124 
urapidil, have short half-lives due to competitive inhibition and displacement by endogenous 125 
catecholamines. The shorter half-life of selective α1-adrenoceptor antagonists results in less 126 
reflex tachycardia and a shorter duration of post-operative hypotension. In contrast, modified 127 
release doxazosin has a longer duration of action (t1/2 = 16-36 hours), allowing once daily 128 
dosing as well as dose optimisation in the days prior to surgery. In general, doxazosin does 129 
not cause reflex tachycardia or significant post-operative hypotension. 130 
Several retrospective studies have reported the benefit of preoperative blockade with PBZ 131 
using endpoints such as operative mortality, intraoperative blood pressure excursions and 132 
post-operative complications.4, 15-17 There is no published randomised clinical trial data 133 
comparing PBZ with selective alpha-blockade. One retrospective study found no difference 134 
in blood pressure or intraoperative/post-operative fluid requirements between patients pre-135 
treated with PBZ versus doxazosin or prazosin.18 Another retrospective multi-centre study 136 
reported higher post-operative inotropic requirements in patients pre-treated with PBZ and 137 
higher intraoperative blood pressure readings in those who received doxazosin.19 138 
Evidence for efficacy of selective alpha1-adrenoceptor antagonists in the preoperative 139 
management of PPGLs exists mainly for doxazosin (DX).19, 21 In one study DX performed as 140 
well as PBZ with respect to intraoperative haemodynamic stability, with fewer reported side-141 
effects, episodes of intraoperative tachycardia and post-operative fluid requirements, and no 142 
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difference in mortality.21 In contrast, other groups observed that pre-treatment with DX 143 
resulted in higher systolic blood pressures before and after anaesthetic induction compared 144 
with PBZ.23 Van der Zee and colleagues recently reviewed studies comparing pre-treatment 145 
with PBZ versus DX, and concluded that there was no evidence to suggest superiority of one 146 
agent over the other, and that alpha-adrenoceptor blockade per se was efficacious.22 In 147 
another retrospective series, preoperative treatment with prazosin was associated with no 148 
deaths, although significant intraoperative hypertensive surges occurred in 83% of treated 149 
patients.21  Successful surgical outcomes following preoperative urapidil administration have 150 
also been reported. However, hypertensive surges occurred at induction and/or tumour 151 
manipulation in all patients. Esmolol administration was required to control intraoperative 152 
tachycardia in one third of cases.23  153 
One retrospective study reported no benefit of preoperative alpha-blockade in normotensive 154 
patients with secretory PPGL. It is important to note that the number of subjects in the 155 
treatment group was almost twice that of the control group and that a modest dose of DX 156 
(4mg) was used in the treatment group. No difference was seen in intraoperative blood 157 
pressure in patients treated with DX compared with patients who did not receive alpha-158 
adrenoceptor blockade. There was, however, increased administration of intraoperative 159 
inotropes and colloid in the DX-treated group.25  160 
2. Beta-adrenoceptor antagonists 161 
β-adrenoceptor antagonists are contraindicated in the absence of effective α1-receptor 162 
blockade due to the risk of a potentially fatal hypertensive crisis secondary to unopposed 163 
alpha-adrenoceptor stimulation.6 Preoperative use of β-blockers is generally reserved for 164 
prevention and treatment of cardiac arrhythmias and reflex tachycardia, and no evidence 165 
exists to support the routine use of beta-blockade in the management of noradrenaline-166 
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secreting tumours in the absence of arrhythmias.1 However, preoperative use of β-blockers 167 
should be considered in the management of tachycardia or tachyarrhythmias induced by 168 
adrenaline-secreting PPGL. Cost and dosing schedules may need to be considered when 169 
choosing a beta-adrenoceptor antagonist (the latter to maximise compliance).  170 
3. Calcium channel antagonists 171 
Calcium channel antagonists (CCB) inhibit noradrenaline-mediated calcium influx into 172 
vascular smooth muscle thereby inducing coronary and peripheral artery relaxation to control 173 
hypertension, tachyarrhythmias and possibly coronary vasospasm.14 These agents cause 174 
minimal hypotension and may be best suited for normotensive patients with paroxysmal 175 
hypertension or intolerance to alpha-adrenoceptor antagonists.6  176 
Brunaud et al compared patients treated with nircardipine with patients treated with PBZ and 177 
beta-blockade and found that intraoperative mean systolic blood pressure and 178 
incidence/duration of hypertensive surges was lower in PBZ-treated patients.26 However, 179 
postoperatively, PBZ-treated patients had an increased incidence of hypotension and greater 180 
fluid requirements. No difference in overall haemodynamic stability was observed between 181 
groups.25 Similarly, Siddiqi et al reported no difference in haemodynamic stability between 182 
patients treated with either nicardipine or PBZ, although patients pre-treated with the former 183 
had a smaller mean tumour size and lower metanephrine levels.24 Finally, in another 184 
retrospective series, nicardipine monotherapy was associated with low mortality rates but 185 
increased incidence of intraoperative hypertensive episodes.25 186 
4. α-methyl-para-tyrosine (Metyrosine) 187 
Metyrosine competitively inhibits tyrosine hydroxylase, the enzyme that regulates the rate-188 
limiting step of catecholamine biosynthesis14, to reduce catecholamine levels.  Metyrosine is 189 
most often used in conjunction with alpha-blockade, and in combination may reduce both 190 
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intraoperative haemodynamic instability and postoperative cardiovascular morbidity. 191 
However, high cost, limited availability and intravenous route of administration restrict 192 
routine use. Metyrosine has been reported to provide improved haemodynamic stability and 193 
reduced postoperative fluid requirements, although no differences in surgical outcome.28,29,30 194 
It is important to note however, that hypertensive crises may still occur with metyrosine 195 
monotherapy.5 196 
 197 
When should add-on therapy be considered? 198 
Add-on therapy should be considered when blood pressure is not adequately controlled with a 199 
single agent or the patient is intolerant of escalating doses of monotherapy. In either setting, 200 
metyrosine or CCB can be used effectively as add-on therapies to alpha-adrenoceptor 201 
antagonists and, in combination, have been found to provide superior haemodynamic stability 202 
in some studies.26, 28 Add-on therapy should also be used to treat tachycardia or cardiac 203 
arrhythmias, with beta-adrenoceptor antagonists the preferred agents. 204 
 205 
When should pre-operative alpha-blockade be discontinued? 206 
Limited data exists to inform this decision and discontinuation of treatment the night prior 207 
versus the morning of surgery is guided by the choice of alpha-blockade and half-life of the 208 
agent. For example, PBZ has a longer half-life and in patients scheduled for an early morning 209 
theatre slot treatment is generally continued until the evening prior to surgery; however, this 210 
approach is not universal with some clinicians advising a final dose on the morning of 211 
surgery. Where a selective alpha-blocker with a shorter duration of action is used, the last 212 
dose is usually administered on the day of surgery.  213 
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 214 
Do all patients require preoperative fluid replacement? 215 
There is no randomised controlled evidence to support a role for routine preoperative fluid 216 
replacement.  However, retrospective data suggests that fluid and salt replacement may limit 217 
postural hypotension and post-operative hypotension3 by optimising intravascular status. If 218 
patients are unable to tolerate a high fluid intake orally, administration of intravenous fluids 219 
for 24-48 hours before surgery is often advised. However, the requirement for preoperative 220 
intravenous fluid has been queried, as Lentschener and colleagues observed no difference in 221 
mortality when intravenous fluids were given on an ‘as needed’ basis only, as guided by 222 
arterial blood pressure7, indicating that ‘prophylactic’ administration of intravenous fluids 223 
may not improve outcomes in PPGL surgery when appropriate anaesthetic expertise is readily 224 
available. 225 
 226 
What is the value of perioperative management? 227 
Even when preoperative blockade is carefully managed, and optimal alpha-adrenoceptor 228 
blockade and fluid replacement is deemed to have been achieved, intraoperative 229 
haemodynamic instability can still occur as illustrated in Figures 1A and 1B. Moreover, in 230 
some instances, such as emergency surgery in patients with a known phaeochromocytoma, it 231 
may not be possible to establish adequate preoperative blockade prior to surgery; however 232 
safe clinical outcomes can still be achieved.  Figure 1C illustrates such a case, suggesting that 233 
perioperative management may actually be more critical for achieving good clinical 234 
outcomes than administration of preoperative hypotensive drugs. This thesis is supported by 235 
recent reports which reason that adequate control of intraoperative hypertension can be 236 
achieved through meticulous blood pressure monitoring, careful surgical practice and 237 
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administration of fast-acting hypotensive agents when necessary.32, 33 Consistent with this, 238 
several studies have shown that in the perioperative period, continuous blood pressure 239 
monitoring, administration of vasoactive and anti-arrhythmic drugs, and careful fluid 240 
management all contribute to improved patient outcomes.7, 10, 11 241 
 242 
Conclusions 243 
There is a lack of available randomised clinical trial data to support decision-making on pre-244 
operative management of PPGL. Currently, however, ‘PRESCRIPT’ (see clinicaltrials.gov), a 245 
randomised, multi-centre open label clinical trial is recruiting subjects to determine whether 246 
preoperative treatment with PBZ or DX is superior with regards to minimising intraoperative 247 
haemodynamic instability.  Until these data are reported, current recommendations and 248 
available evidence support PBZ (or, where not available, DX) as first line preoperative 249 
pharmacological therapy in patients with PPGLs. In the majority of cases, a short period of 250 
preoperative blockade with PBZ, combined with active fluid management, allows surgery to 251 
proceed uneventfully. However, even when the patient’s clinical status is deemed to have 252 
been ‘optimised’ prior to surgery, significant intraoperative blood pressure excursions may 253 
still occur. There is growing evidence that perioperative anaesthetic expertise is critical for 254 
successful management of patients with PPGL undergoing surgery, and we believe that this 255 
may in fact be the single most important factor-governing outcome.  256 
  257 
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FIGURE LEGEND: 396 
 397 
Fig. 1 Intraoperative haemodynamic changes in three patients undergoing 398 
adrenalectomy for phaeochromocytoma.  399 
 400 
(A) 68-year old man (70kg): plasma metadrenaline 1,283 pmol/L (RR: 0–600) and 401 
normetadrenaline 1,086 pmol/L (RR: 0–1000).  Computed tomography (CT) imaging 402 
revealed a 9.0 x 4.5cm phaeochromocytoma. Preoperative blockade was established with 403 
phenoxybenzamine over a five-week period (maximum tolerated dose 20mg twice daily) 404 
and propranolol (10mg thrice daily) in accordance with published guidelines.3 A 405 
minimum 2.5L oral fluid intake per day was advised while taking phenoxybenzamine. He 406 
also received 5L of 0.9% sodium chloride intravenously in the 48 hour period prior to 407 
surgery. There were no postoperative complications. 408 
 409 
(B) 72-year old man (85.2kg): plasma metadrenaline 427 pmol/L (RR: 0–600) and plasma 410 
normetadrenaline 17,187 pmol/L (RR: 0–1000). CT revealed a 12.5 x 11.5cm right-sided 411 
phaeochromocytoma.  Preoperative blockade was established with phenoxybenzamine 412 
over a seven-week period (maximum tolerated dose 20mg twice daily). As the patient 413 
was clinically hypovolemic at initiation of phenoxybenzamine treatment, 3L of oral fluid 414 
intake per day was supplemented with 2L of 0.9% sodium chloride intravenously as an 415 
outpatient on our endocrine day unit, and a further 6L of intravenous fluid in the 48h 416 
preoperatively. There were no postoperative complications.  417 
 418 
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(C)  75-year old man (65.8kg): plasma metadrenaline >18,000pmol/L (RR: 0–600) and 419 
plasma normetadrenaline 10,120 pmol/L (RR:0–1000). CT revealed a 5 x 7cm right-420 
sided phaeochromocytoma. The patient declined medical or surgical management. 421 
However, shortly afterwards he presented with acute small bowel obstruction 422 
necessitating emergency surgery in the absence of preoperative blockade. A right 423 
adrenalectomy was performed during the same procedure. There were no postoperative 424 
complications.  425 
 426 
Key: Art line, arterial line; HR, heart rate; IBP, invasive blood pressure; NIBP, non-invasive 427 
blood pressure; solid arrow indicates time of anaesthetic induction/intubation; dashed arrow 428 
signifies the point at which the PPGL was removed.  429 
A.
B.
C.
Figure 1.
